Pathogenetic approach to the treatment of autonomic diabetic neuropathy: the place of alpha-lipoic acid preparations

• Tatyana N. Soluyanova

Abstract

This article reviews the data on the pathogenesis, clinical features, and validity of antioxidant therapy in аutonomic diabetic neuropathy. The relevance of studying of this problem is due to the fact that cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in patients with diabetes mellitus. CVD in type 2 diabetes is diagnosed 2-5 times more often, and mortality from CVD in diabetes reaches 75% of cases. Therefore, early detection of cardiovascular risks, including those associated with cardiac neuropathy, is a priority for the prevention of mortality from diabetic complications.

Keywords:pathogenesis, clinical features, antioxidant therapy, autonomic diabetic neuropathy, cardiovascular diseases, type 2 diabetes mellitus, cardiac neuropathy, prevention of mortality

References

1. Dedov I.I., Shestakova M.V., Mayorov A.Yu., eds. Standards of specialized diabetes care. 9th edition. Diabetes. Moscow: UP PRINT; 2019. doi: 10.14341/DM221S 1 (in Russian)

URL: https://dia-endojournals.ru/dia/article/view/12211

DOI: https://doi.org/10.14341/DM221S1

2. Endocrinology: national leadership. Edited by I.I. Dedov, G.A. Melnichenko. Moscow: GEOTAR-Media; 2014: 1072 p. (in Russian)

3. IDF Clinical Practice Recommendations on the Diabetic Foot, 2017.

4. Diabetes mellitus: acute and chronic complications. Edited by I.I. Dedov, M.V. Shestakova. Moscow; 2011: 480 p. (in Russian)

5. Biryukova E.V. Complications in diabetes mellitus: diabetic neuropathy focus. Meditsinskiy sovet [Medical Council]. 2018; (4): 48-52. (in Russian)

6. Levin O.S. Polyneuropathies. Moscow: Meditsinskoe informatsi-onnoe agentstvo [Medical News Agency]; 2011: 498 p. (in Russian)

7. Kalinin A.P., Kotov S.V., Rudakova I.G. Neurological disorders in endocrine diseases: a guide for doctors. Meditsinskoe informatsionnoe agentstvo [Medical News Agency]; 2009: 488 p. (in Russian)

8. Boulton A.J., Gries F.A. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. In: Textbook of diabetic neuropathy. Stuttgart: Thieme, 2002: 378-85.

9. Vinik A.I., Park T.S., Stansberry K.B., Pittenger G.L. Diabetic neuropathies. Diabetologia. 2000; 43 (8): 957-73.

10. Order of the Ministry of Health of Russia of December 28, 2012 No. 1577n On the approval of the standard of primary health care for diabetic polyneuropathy. (in Russian)

11. Order of the Ministry of Health of Russia dated December 24, 2012 No. 1544n On the approval of the standard of specialized medical care for diabetic polyneuropathy. (in Russian)

12. Ametov A.S., Strokov I.A., Barinov A.N., et al.Alpha lipoic acid in the treatment of symptomatic diabetic polyneuropathy: symptomatic diabetic neuropathy (SYDNEY) trial. Farmateka.[Pharmateca] 2004; (11): 69-73. (in Russian)

13. Stevens M.J., Obrosova I., Cao X., et al. Effect of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes. 2000; 49: 1006-15.

14. Hermann R., Niebch G. Human pharmacokinetics of a-lipoic acid. In: J. Fuchs, L. Packer, G. Zimmer (eds). Lipoic Acid in Health and Disease. New York: Marcel Dekker, 1997. P. 337-360.

15. Palacka P., Kucharska J., Murin J., Dostalova K., et al. Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl Lek Listy. 2010; 111: 205-11.

16. Ansar H., Mazloom Z., Kazemi F., Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J. 2011; 32: 584-8.

17. Gianturco V., Bellomo A., D’Ottavio E., Formosa V., et al. Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? Arch Gerontol Geriatr. 2009; 49 (suppl): 129-33.

18. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813-20.

19. Koh E.H., Lee W.J., Lee S.A., Kim E.H. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011; 124: 851-8.

20. Rahman S.T., Merchant N., Haque T., Wahi J., et al. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension results from the quality study. J Cardiovasc Pharmacol Ther. 2012; 17: 139-45.

21. Nguyen N., Takemoto J.K. A case for alpha-lipoic acid as an alternative treatment for diabetic polyneuropathy. J Pharm Pharm Sci. 2018; 21 (1s): 177s-91s.

22. Lee S.J., Jeong S.J., et al. Effects of high-dose a-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J. 2017; 41 (4): 275-83.

23. Ametov A.S., Mamedova I.N. Treatment of peripheral autonomic insufficiency with alpha-lipoic acid (Berlithione) in patients with type 2 diabetes mellitus. Klinicheskaya farmakologiya i terapiya [Clinical pharmacology and therapy]. 2003; (2): 74-80. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)